Pharmaceutical Research and Manufacturers of America (PhRMA) controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2026
PhRMA sues to block CMS GLOBE most-favored-nation drug pricing model for Medicare Part B
Lawsuit filed
The Pharmaceutical Research and Manufacturers of America (PhRMA) filed a lawsuit on Wednesday (October 7, 2026) in the US District Court for the District of Columbia challenging the CMS Global Benchmark for Efficient Drug Pricing (GLOBE) model, a mandatory "most favored nation" pricing policy for Medicare Part B set to take effect on January 1, 2027. PhRMA alleges that GLOBE is unlawful and exceeds CMS's statutory authority, that the agency is using limited demonstration model authority to impose nationwide price-setting policies Congress never authorized, and that benchmarks relying on quality-adjusted life-years can discriminate against people with disabilities, chronic conditions, and rare diseases. The lawsuit asks the court to declare GLOBE unlawful and vacate the rule in its entirety.
Source excerpt
The complaint argues that GLOBE is unlawful and exceeds the statutory authority of CMS.
it is set to take effect January 1, 2027